创伤患者输注冷沉淀可减轻纤维蛋白溶解并恢复正常的血凝块结构与稳定性:FEISTY试验的实验室子研究结果
本研究为FEISTY随机对照试验(NCT02745041)的实验室子研究,比较创伤患者输注冷沉淀(cryo)与纤维蛋白原浓缩物(Fg-C;Riastap)前后配对血浆样本的血凝块强度与纤溶稳定性。结果显示两组输注后纤维蛋白原浓度均显著升高;冷沉淀输注后纤溶酶生成速率降低1.5倍,而Fg-C输注后无变化。冷沉淀输注后纤溶酶原激活物抑制剂1活性和抗原水平及因子XIII抗原升高,Fg-C则无此变化。共聚焦显微镜显示冷沉淀输注后纤维蛋白结构与对照血凝块相似,而Fg-C输注后血凝块仍多孔且纤维短小;冷沉淀而非Fg-C治疗增加单根纤维的韧性和刚度。
要点
- 创伤患者输注冷沉淀后纤溶酶生成速率降低1.5倍,而输注纤维蛋白原浓缩物(Fg-C;Riastap)后无变化。
- 冷沉淀输注后纤溶酶原激活物抑制剂1活性和抗原水平及因子XIII抗原升高,Fg-C输注后未升高。
- 共聚焦显微镜显示冷沉淀输注后纤维蛋白结构与对照血凝块相似,Fg-C输注后血凝块仍多孔且纤维短小。
- 冷沉淀而非Fg-C治疗增加单根纤维的韧性和刚度。
- 两组输注后纤维蛋白原浓度均显著升高。
适用人群与场景
- FEISTY试验中的创伤患者,比较冷沉淀与纤维蛋白原浓缩物(Fg-C;Riastap)输注前后的配对血浆样本
研究设计与关键结果
- 研究类型:FEISTY随机对照试验(NCT02745041)的实验室子研究,比较创伤患者输注冷沉淀与纤维蛋白原浓缩物(Fg-C;Riastap)前后配对血浆样本。
- 两组输注后纤维蛋白原浓度均显著升高。
- 冷沉淀输注后纤溶酶生成速率降低1.5倍,Fg-C输注后纤溶酶生成速率无变化。
- 冷沉淀输注后纤溶酶原激活物抑制剂1活性和抗原水平及因子XIII抗原升高,Fg-C输注后未升高。
- 共聚焦显微镜显示冷沉淀输注后纤维蛋白结构与对照血凝块相似,Fg-C输注后血凝块仍多孔且纤维短小。
- 冷沉淀而非Fg-C治疗增加单根纤维的韧性和刚度。
证据类型、等级与局限
- 证据类型:随机对照试验(FEISTY;NCT02745041)的实验室子研究(离体实验室研究)。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为,离体实验室研究数据表明冷沉淀输注恢复关键纤溶调节因子并限制纤溶酶生成,从而形成更强的血凝块。
- 作者认为,这是首个研究冷沉淀与Fg-C之间血凝块稳定性和结构差异的研究,表明冷沉淀中的额外因子允许形成更强、更稳定的血凝块。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Fibrinogen is the first coagulation protein to reach critical levels during traumatic haemorrhage. This laboratory study compares paired plasma samples pre- and post-fibrinogen replacement from the Fibrinogen Early In Severe Trauma studY (FEISTY; NCT02745041). FEISTY is the first randomised controlled trial to compare the time to administration of cryoprecipitate (cryo) and fibrinogen concentrate (Fg-C; Riastap) in trauma patients. This study will determine differences in clot strength and fibrinolytic stability within individuals and between treatment arms.
METHODS: Clot lysis, plasmin generation, atomic force microscopy and confocal microscopy were utilised to investigate clot strength and structure in FEISTY patient plasma.
RESULTS: Fibrinogen concentration was significantly increased post-transfusion in both groups. The rate of plasmin generation was reduced 1.5-fold post-transfusion of cryo but remained unchanged with Fg-C transfusion. Plasminogen activator inhibitor 1 activity and antigen levels and Factor XIII antigen were increased post-treatment with cryo, but not Fg-C. Confocal microscopy analysis of fibrin clots revealed that cryo transfusion restored fibrin structure similar to those observed in control clots. In contrast, clots remained porous with stunted fibres after infusion with Fg-C. Cryo but not Fg-C treatment increased individual fibre toughness and stiffness.
CONCLUSIONS: In summary, our data indicate that cryo transfusion restores key fibrinolytic regulators and limits plasmin generation to form stronger clots in an ex vivo laboratory study. This is the first study to investigate differences in clot stability and structure between cryo and Fg-C and demonstrates that the additional factors in cryo allow formation of a stronger and more stable clot.
参考来源
- Morrow GB, Feller T, McQuilten Z, et al. Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: Results from a laboratory sub-study of the FEISTY trial. Crit Care. 2022. PMID: 36163263. doi:10.1186/s13054-022-04167-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。